Have a feature idea you'd love to see implemented?
Let us know!
ANRO Alto Neuroscience Inc.
Price (delayed)
$4.09
Market cap
$110.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.96
Enterprise value
-$55.82M
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Building on more than a decade of
Highlights
The EPS has increased by 44% year-on-year and by 27% since the previous quarter
ANRO's quick ratio has surged by 52% year-on-year but it is down by 34% since the previous quarter
The company's net income has shrunk by 75% YoY and by 15% QoQ
The debt has surged by 65% year-on-year and by 60% since the previous quarter
Key stats
What are the main financial stats of ANRO
Market
Valuations
Earnings
Shares outstanding
26.97M
Market cap
$110.31M
Enterprise value
-$55.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$56.05M
EBITDA
-$55.43M
Free cash flow
-$47.85M
Per share
Balance sheet
Liquidity
EPS
-$4.96
Free cash flow per share
-$1.77
Book value per share
$6.12
Revenue per share
$0
TBVPS
$7.11
Total assets
$191.61M
Total liabilities
$26.56M
Debt
$16.07M
Equity
$165.05M
Working capital
$169.51M
Debt to equity
0.1
Current ratio
13.09
Quick ratio
13
Net debt/EBITDA
3
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.5%
Return on equity
-49.3%
Return on invested capital
-754.2%
Return on capital employed
-31.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANRO stock price
How has the Alto Neuroscience stock price performed over time
Intraday
-4.22%
1 week
-11.09%
1 month
-71.38%
1 year
N/A
YTD
N/A
QTD
-64.25%
Financial performance
How have Alto Neuroscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.38M
Net income
-$57.45M
Gross margin
N/A
Net margin
N/A
Alto Neuroscience's operating income has shrunk by 86% YoY and by 17% QoQ
The company's net income has shrunk by 75% YoY and by 15% QoQ
Growth
What is Alto Neuroscience's growth rate over time
Valuation
What is Alto Neuroscience stock price valuation
P/E
N/A
P/B
0.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 44% year-on-year and by 27% since the previous quarter
ANRO's equity is down by 8% QoQ
Efficiency
How efficient is Alto Neuroscience business performance
The return on assets is up by 46% year-on-year and by 8% since the previous quarter
The ROE has increased by 41% QoQ
Alto Neuroscience's ROIC has decreased by 36% YoY but it has increased by 7% from the previous quarter
Dividends
What is ANRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANRO.
Financial health
How did Alto Neuroscience financials performed over time
The total liabilities has soared by 54% YoY and by 51% QoQ
ANRO's quick ratio has surged by 52% year-on-year but it is down by 34% since the previous quarter
The debt is 90% smaller than the equity
ANRO's debt to equity has soared by 163% YoY and by 67% from the previous quarter
The debt has surged by 65% year-on-year and by 60% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.